Plain-English translation of NCT07178431 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called , which uses specially modified immune cells to help control multiple sclerosis that has not improved with standard medications. The treatment involves collecting some of your immune cells, growing more of them in a laboratory, and then putting them back into your body. Researchers want to see if this approach can stop or slow disease activity and improve quality of life.
Some people with multiple sclerosis continue to have disease activity—such as relapses, worsening disability, or new brain lesions—even when taking the strongest available medications. This trial exists to test whether this new cell-based treatment could help people whose MS has proven difficult to control with current standard therapies.
You likely qualify if…
You likely don't qualify if…
If you qualify and join this trial, you will undergo a procedure called leukapheresis to collect some of your immune cells. You will then receive chemotherapy to prepare your body, followed by infusion of the newly grown cells back into your bloodstream. Researchers will monitor you closely over time to check for side effects and to see whether the treatment reduces your MS disease activity. The trial has two phases: Phase I focuses on finding the right dose and confirming safety, while Phase II tests how well the treatment works in a larger group of patients at that dose.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
Germany
Phase
Safety & dosing / Early efficacy
Sponsor
Miltenyi Biomedicine GmbH
Enrollment target
~26 participants
Started
April 2026
Primary completion
August 2030
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Clinical Trial Manager
Charite University, Berlin, Germany
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.